Global Head and Neck Cancer Therapeutics Market stood at USD2024.33 million in 2021 and is expected to grow at an impressive rate of 7.22% during the forecast period. This can be ascribed to the growing popularity of precision medicine and the need for new therapies for the treatment of different types of head and neck cancers. Furthermore, growing consumption of tobacco and alcohol is further contributing to the increasing incidences of head and neck cancers. According to World Health Organization, Tobacco kills nearly half of its users, accounting for around 8 million deaths every year. Out of which, 7 million deaths are caused due to direct tobacco use, while the remaining is caused due to the exposure of nonsmokers to passive smoking.

Increasing Number of Clinical Trials

The increasing research & development activities related to the development of different types of therapies related to head and neck cancer has significantly augmented the number of clinical trials related to the same. There are around 2957 clinical trials launched on head and neck cancer till date. In 2021, around 52 clinical trials were launched globally related to head and neck cancer. This count is expected to increase in the coming years, thereby supporting the market growth in the coming years.

Growing Adoption of New Treatments

Development of immunotherapies, CAR-T cell therapies, among others for the treatment of different types of cancer is expected to drive the growth of head and neck cancer therapeutics market. Several clinical trials related to immunotherapies and targeted therapies are going on. In the forecast period, several advanced therapies can be expected to treat head and neck cancer.

Increasing Number of Players

Many healthcare players are either developing drugs or therapies for the treatment of head and neck cancer or collaborating with other companies who have developed the therapy or drug earlier. Some healthcare majors are simply acquiring the smaller ones and expanding their portfolio of head and neck cancer therapeutic solutions. This, in turn, is leading to a lot of investment in the head and neck cancer therapeutics industry. For instance, in January 2021, AbbVie, Inc. developed SkinMedica Neck Correct Cream, which focuses on the biology of the skin on the neck and decollete area.


Click here to download the sample

Market Segmentation

The global head and neck cancer therapeutics market is segmented by type, diagnostic methods, treatment type, disease indication, route of administration, therapeutic class, end user, region, and company. Based on type, the global head and neck cancer therapeutics market can be split into diagnostic methods and treatment types. Diagnostics methods can be further categorized into Biopsy, Imaging, Endoscopy and Others. While treatment type can be further fragmented into Surgery, Radiation Therapy, Chemotherapy, Immunotherapy and Targeted Therapy. Disease indication segment can be fragmented into Lip and Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal Cancer, Nasopharyngeal Cancer, Salivary Gland Cancer and Hypopharyngeal Cancer. The Route of Administration can be split into Injectable and Oral. Therapeutic Class can be categorized as PD Inhibitors (PD-1 and PD-L1), EGFR Inhibitors and Microtubule Inhibitors. In terms of end user, the global head and neck cancer therapeutics market can be categorized as Hospitals, Specialty Clinics, Ambulatory Surgical Centers, And Others. Regionally, the Head and Neck Cancer Therapeutics Market can be categorized into North America, Asia Pacific, Europe, South America, and Middle East & Africa. North America dominates the overall Head and Neck Cancer Therapeutics Market with United States having the biggest market. The United States Head and Neck Cancer Therapeutics Market stood at USD562.21 million in 2021.

Major companies in the market are Eli Lilly and Company, Bristol Myers Squibb Company, Sanofi S.A., Merck & Co., Inc., Pfizer Inc, AbbVie Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Fresenius Medical Care AG & Co. KGaA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, AstraZeneca Plc., Astellas Pharma Inc., AB Science SA, Boston Biomedical, Inc., among others. Major players operating in the market are following strategies such as mergers and acquisitions, new therapy or drug launches, and others to stay competitive and have an edge over other players in the market.

Attribute

Details

Market Size Value in 2021

USD2024.33 million

Revenue Forecast in 2027

USD3126.26 million

United States Market Size Value in 2021

USD562.21 million

Growth Rate

7.22%

Base Year

2021

Historical Years

2017 – 2020

Estimated Year

2022

Forecast Period

2023 – 2027

Quantitative Units

Revenue in USD Million and CAGR for 2017-2021 and 2022-2027

Report Coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered

·         Type

o   Diagnostic Methods

o   Treatment Type

§  Disease Indication

§  Route of Administration

§  Therapeutic Class

·         End User

Regional Scope

North America; Asia Pacific; Europe, South America; Middle East & Africa

Country Scope

United States; Canada; Mexico; Germany; France; United Kingdom; Italy; Spain; China; India; Japan; Australia; South Korea; Singapore; Brazil; Argentina; Colombia; South Africa; Saudi Arabia; UAE

Key Companies Profiled

Eli Lilly and Company, Bristol Myers Squibb Company, Sanofi S.A., Merck & Co., Inc., Pfizer Inc, AbbVie Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Fresenius Medical Care AG & Co. KGaA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, AstraZeneca Plc., Astellas Pharma Inc., AB Science SA, Boston Biomedical, Inc.

Customization Scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and Purchase Options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

 

Report Scope:

In this report, global Head and Neck Cancer Therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Head and Neck Cancer Therapeutics Market, By Type:
    • Diagnostic Methods
      • Biopsy
      • Imaging
      • Endoscopy
      • Others
    • Treatment Type
      • Surgery
      • Radiation Therapy
      • Chemotherapy
      • Immunotherapy
      • Targeted Therapy
  • Head and Neck Cancer Therapeutics Market, By Disease Indication:
    • Lip and Oral Cavity Cancer
    • Laryngeal Cancer
    • Oropharyngeal Cancer
    • Salivary Gland Cancer
    • Nasopharyngeal Cancer
    • Hypopharyngeal Cancer
  • Head and Neck Cancer Therapeutics Market, By Route of Administration:
    • Injectable
    • Oral
  • Head and Neck Cancer Therapeutics Market, By Therapeutic Class:
    • PD Inhibitors
    • EGFR Inhibitors
    • Microtubule Inhibitors
  • Head and Neck Cancer Therapeutics Market, By End User:
    • Hospitals
    • Specialty Clinics
    • Ambulatory Surgical Centers
    • Others
  • Head and Neck Cancer Therapeutics Market, By Region:
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • United Kingdom
      • Italy
      • Spain
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • Singapore
    • South America
      • Brazil
      • Argentina
      • Colombia
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global Head and Neck Cancer Therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com

1.    Product Overview

2.    Research Methodology

3.    Executive Summary

4.    Voice of Customer

4.1.  Brand Awareness

4.2.  Preferred Diagnostic Method

4.3.  Preferred Treatment Type

4.4.  Preferred Route of Administration

5.    Global Head and Neck Cancer Therapeutics Market Outlook

5.1.  Market Size & Forecast

5.1.1.     By Value

5.2.  Market Share & Forecast

5.2.1.     By Type (Diagnostic Methods v/s Treatment Type)

5.2.1.1.         By Diagnostic Methods (Biopsy, Imaging, Endoscopy, Others)

5.2.1.2.         By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy)

5.2.1.2.1.             By Disease Indication (Lip and Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal Cancer, Hypopharyngeal Cancer)

5.2.1.2.2.             By Route of Administration (Injectable, Oral)

5.2.1.2.3.             By Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors)

5.2.1.3.         By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)

5.2.2.     By Region

5.2.3.     By Company (2021)

5.3.  Product Market Map

6.    North America Head and Neck Cancer Therapeutics Market Outlook

6.1.  Market Size & Forecast          

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Type

6.2.1.1.         By Diagnostic Methods

6.2.1.2.         By Treatment Type

6.2.1.2.1.             By Disease Indication

6.2.1.2.2.             By Route of Administration

6.2.1.2.3.             By Therapeutic Class

6.2.1.3.         By End User

6.2.2.     By Country

6.3.  North America: Country Analysis

6.3.1.     United States Head and Neck Cancer Therapeutics Market Outlook

6.3.1.1.         Market Size & Forecast

6.3.1.1.1.             By Value

6.3.1.2.